NYSE: CICigna

    Cigna Q3 2026 Results: Net Income $1.44 Billion on Revenue of $73.68 Billion

    • US stocks
    • Earnings
    • Health Care
    Lab technicians in blue scrubs working with automated analysis machines in a bright clinical laboratory
    Esculab, via Wikimedia Commons (CC0). Illustrative image.

    Cigna (NYSE: CI) reported third quarter 2026 results for the quarter ended 30 Sep 2026, with GAAP revenue of $73.7 billion and GAAP shareholders' net income of $1.44 billion, and it said on 5 Nov 2026 that it had raised its 2026 outlook. Diluted EPS was $5.47 on a GAAP basis, and adjusted income from operations, a company-defined measure, was $7.98 per share.

    Key highlights

    • Revenue (GAAP): $73.7 billion, up 5.6% YoY and 2.8% QoQ
    • Shareholders' net income (GAAP): $1.44 billion, down 22.8% YoY and 13.1% QoQ
    • Diluted EPS (GAAP): $5.47, down 21.6% YoY
    • Adjusted income from operations (company-defined): $7.98 per share
    • 2026 adjusted income from operations outlook (company-defined): at least $30.60 per share

    Summary

    Consolidated (GAAP) $ million
    ParticularsQ3 2026Q3 2025YoYQ2 2026QoQ
    Revenue73,683.069,748.0+5.6%71,668.0+2.8%
    1,442.01,868.0-22.8%1,660.0-13.1%
    Diluted EPS ($)5.476.98-21.6%6.29-13.0%

    Figures are in $ million except EPS; YoY compares with Q3 2025 and QoQ with Q2 2026. Q3 2026 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.

    The table shows revenue of $73.7 billion for the third quarter of 2026, up 5.6% from a year earlier and up 2.8% from the second quarter of 2026. Shareholders' net income was $1.44 billion, down 22.8% from a year earlier and down 13.1% from the second quarter.

    Net income was 2.0% of revenue this quarter, against 2.7% a year earlier, which is 0.7 percentage points lower. The table gives diluted EPS of $5.47, down 21.6% from $6.98 a year earlier.

    Adjusted income from operations was stable

    The company says its adjusted income from operations, a non-GAAP measure, excludes net investment gains and losses, amortization of acquired intangible assets and special items from shareholders' net income. The figure was $2,104 million, or $7.98 per share, against $2,096 million, or $7.83 per share, a year earlier. The release names special items in the quarter including a strategic optimization program ($85 million pre-tax) and litigation charges ($60 million pre-tax).

    Pharmacy Benefit Services fell while Cigna Healthcare rose

    Pharmacy Benefit Services adjusted income from operations, before tax, decreased 22%, which the company attributes primarily to large client contract renewals and strategic investments. Cigna Healthcare adjusted income from operations, before tax, was $1,193 million, up 15%, which the company attributes primarily to higher net investment income and improved operating efficiency.

    2026 outlook raised to at least $30.60 per share

    The company now expects 2026 adjusted income from operations of at least $30.60 per share, a change of +$0.15 from its prior projection, and at least $4,600 million of pre-tax adjusted income from operations for Cigna Healthcare. The company says the outlook includes expected future share repurchases and anticipated 2026 dividends.

    Inference

    The company repurchased 1.8 million shares for approximately $500 million year to date through 4 Nov 2026. Weighted average shares were 263,788 thousand in the quarter, against 267,530 thousand a year earlier, and shareholders' equity per share was $164.70 at 30 Sep 2026.

    The release gives no GAAP full-year 2026 EPS outlook. The next dated step is the company's planned exit from Individual and Family Plans, which takes effect on 1 Jan 2027 and was announced in April 2026.

    Filed with the US SEC on . Reference: Original filing (SEC)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

    Latest posts